NDRA
Endra Life Sciences
$5.79
−$0.04 (−0.77%)Sep 10, 2026
Key metrics
The numbers that frame NDRA today
- Market cap
- $8.68M
- P/E (TTM)
- -1.5
- EV / FCF
- -0.9
- ROIC
- -223.3%
- Div yield
- 0%
- Debt / equity
- 0.2
- 52wk Low
- $2.96
- 52wk High
- $9.85
Growth
Revenue and earnings trend for NDRA
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about NDRA
Is Endra Life Sciences a good buy?
No. Endra Life Sciences has poor quality and mixed momentum. The setup is weak overall. Growth looks excellent, which supports the long-term business case, but that is not enough to offset the weak setup. We think Endra Life Sciences is selling at a very high price.
What is the market capitalization of NDRA?
Endra Life Sciences's market capitalization is $8.68M.
What is the P/E ratio for NDRA stock?
Endra Life Sciences's current P/E ratio is -1.5.
What is the 52-week high for NDRA stock?
The 52-week high for Endra Life Sciences is $9.85. The current close of $5.79 is 41.3% below that high.
What is the 52-week low for NDRA stock?
The 52-week low for Endra Life Sciences is $2.96. The current close of $5.79 is 95.4% above that low.
Does NDRA stock pay dividends?
Endra Life Sciences does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for NDRA?
Endra Life Sciences's Debt / Equity ratio is 0.16.